Ivonescimab shows 18-fold increased PD-1 binding affinity in presence of VEGF at SITC

Summit Therapeutics Inc.

Poster at SITC 2023 details cooperative binding: 18x higher PD-1 affinity with VEGF present in vitro.
Tetravalent bispecific antibody designed for higher avidity in tumor microenvironment vs. healthy tissue.
Ongoing Phase III trials HARMONi (EGFR-mutated NSCLC) and HARMONi-3 (squamous NSCLC).
Over 950 patients treated with ivonescimab across studies in China, Australia, and Summit territories.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.